Haleon plc is increasing its stake in the Tianjin TSKF Pharmaceutical Co. Ltd from 55% to 88% for RMB 4.465 billion (approximately £0.5 billion) to enhance control over its operations in China. The acquisition, expected to close by the end of 2024, reflects Haleon's commitment to the Chinese market, representing about 40% of its China revenues in FY 2023.